ERBB2 and breast cancer: Pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks, single intravenous injection infusion over 30–60 min) was initially approved by the FDA in 2012, now it is used in combination with trastuzumab and docetaxel to treat patients with HER2-positive metastatic breast cancer (MBC) and a neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) at high risk of recurrence (Amiri-Kordestani et al., 2014; Howie et al., 2019).